Abstract
We have developed a specific and sensitive method aiming atdocetaxel (Taxotere®) determination in plasma of treatedpatients. This involved solid-phase extraction of 1 ml of plasmaonto carboxylic acid (CBA) grafted silica cartridges followed byreversed-phase liquid chromatography with UV detection. The bestselectivity was obtained through the use of C18 Uptisphere® asstationary phase. The low limit of quantitation obtained (LOQ:5 ng/ml) allowed measurements of docetaxel up to 24 hours afterone-hour infusions with low dosages of drug (60 mg/m2). Themethod was applied successfully to monitor docetaxel plasma levelswithin two protocols associating fixed dosages of either methotrexate or gemcitabine with escalating doses of Taxotere®.
Similar content being viewed by others
References
Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F, Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT: Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 51: 4845–4852, 1991
Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB: Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16: 187–196, 1998
Vogel M, Hilsenbeck SG, Depenbrock H, Danhauser-Riedl S, Block T, Nekarda H, Fellbaum C, Aapro MS, Bissery MC, Rastetter J et al.: Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents. Eur J Cancer 29A: 2009–20141993
Eckardt JR: Antitumor activity of docetaxel. Am J Health Syst Pharm 54: S2–S6, 1997
Eisenhauer EA, Vermorken JB: The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 55: 5–30, 1998
Ravdin PM: Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients. Eur J Cancer 33 (Suppl 7): S7–S10, 1997
Valero V: Combination docetaxel/cyclophosphamide in patients with advanced solid tumors. Oncology (Huntingt) 11: 34–36, 1997
Aapro MS: Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer. Oncology (Huntingt) 11: 46–49, 1997
Burris HA 3rd: Docetaxel in combination with fluorouracil for advanced solid tumors. Oncology (Huntingt) 11: 50–52, 1997
Dieras V, Fumoleau P, Kalla S, Misset JL, Azli N, Pouillart P: Docetaxel in combination with doxorubicin or vinorelbine. Eur J Cancer 33: S20–S22, 1997
Mauer AM, Masters GA, Haraf DJ, Hoffman PC, Watson SM, Golomb HM, Vokes EE: Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 16: 159–164, 1998
Ardiet C, Zanetta S, Bernard E, Tranchand B, Droz JP: A solid-phase extraction procedure for docetaxel determination in plasma for pharmacokinetic studies (Abstract) 10th NCI-EORTC Symposium on new drugs in cancer therapy. Amsterdam, June 16–19, 1988; no 481 p 125
Vergniol TC, Bruno R, Montay G, Frydman A: Determination of Taxotere in human plasma by a semi-automated highperformance liquid chromatographic method. J Chromatogr 582: 273–278, 1992
Hempel G, Lehmkuhl D, Krumpelmann S, Blaschke G, Boos J: Determination of paclitaxel in biological fluids by micellar electrokinetic chromatography. J Chromatogr A 745: 173–179, 1996
Loos WJ, Verweij J, Nooter K, Stoter G, Sparreboom A: Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 693: 437–441, 1997
Rosing H, Lustig V, Koopman FP, ten Bokkel Huinink WW, Beijnen JH: Bio-analysis of docetaxel and hydroxylated metabolites in human plasma by high-performance liquid chromatography and automated solid-phase extraction. J Chromatogr B Biomed Sci Appl 696: 89–98, 1997
Guillot A, Ardiet C, Dumortier A, Zanetta S, Rebattu P, Dubin F, Assadourian S, Droz JP: Phase I trial of docetaxel and methotrexate combination in patients with metastatic and urothelial epidermoid carcinoma (Abstract). 10th NCI-EORTC Symposium on new drugs in cancer therapy. Amsterdam, June 16–19, 1988; no 395, p 103
Bissery MC, Vrignaud P, Bayssas M, Lavelle F: Preclinical in vivoactivity of docetaxel-containing combinations. Proc Am Soc Clin Oncol 14: 489, 1995
Rebattu P, Pujol JL, Ardiet C, Quentin X, Droz JP, Dumortier A, Khial F, Schuller MP: Combination of docetaxel (DTX) and gemcitabine (G) in patients with inoperable or metastatic non-small cell lung cancer (NSCLC). A phase I study. (Abstract) 10th NCI-EORTC Symposium on new drugs in cancer therapy. Amsterdam June 16–19, 1988; no 361, p 95
Warner A, Privitera M, Bates D: Standards of laboratory practice: antiepileptic drug monitoring. National Academy of Clinical Biochemistry. Clin Chem 44: 1085–1095, 1998
Valdes R Jr, Jortani SA, Gheorghiade M: Standards of laboratory practice: cardiac drug monitoring. National Academy of Clinical Biochemistry. Clin Chem 44: 1096–1109, 1998
Glantz MJ, Choy H, Akerley W, Kearns CM, Egorin MJ, Rhodes CH, Cole BF: Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and response. Semin Oncol 23: 128–135, 1996
Boos J: Ist die Pharmakokinetik von Cytarabin klinisch relevant? Klin Padiatr 204: 198–203, 1992
Ratain MJ, Mick R: Principles of pharmacokinetics and pharmacodynamics. In: Schilsky RL, Milano GA, Ratain MJ (eds) Principles of Antineoplastic Drug Development and Pharmacology. Marcel Dekker, Inc. 1996, pp 123–141
Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB: Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16: 187–196, 1998
Rights and permissions
About this article
Cite this article
Joseph Ardiet, C., Tranchand, B., Zanetta, S. et al. A Sensitive Docetaxel Assay in Plasma by Solid-Phase Extraction and High Performance Liquid Chromatography – UV Detection: Validation and Suitability in Phase I Clinical Trial Pharmacokinetics. Invest New Drugs 17, 325–333 (1999). https://doi.org/10.1023/A:1006327302041
Issue Date:
DOI: https://doi.org/10.1023/A:1006327302041